AGIHO guideline on evidence-based management of COVID-19 in cancer patients : 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants / Nicola Giesen, Elena Busch, Enrico Schalk, Gernot Beutel, Maria M. Rüthrich, Marcus Hentrich, Bernd Hertenstein, Hans H. Hirsch, Meinolf Karthaus, Yascha Khodamoradi, Philipp Koehler, William Krüger, Michael Koldehoff, Robert Krause, Sibylle C. Mellinghoff, Olaf Penack, Michael Sandherr, Ruth Seggewiss-Bernhardt, Karsten Spiekermann, Rosanne Sprute, Jannik Stemler, Florian Weissinger, Bernhard Wörmann, Hans-Heinrich Wolf, Oliver A. Cornely, Christina T. Rieger, Marie von Lilienfeld-Toal
The novel coronavirus SARS-CoV-2 and the associated infectious disease COVID-19 pose a significant challenge to healthcare systems worldwide. Patients with cancer have been identified as a high-risk population for severe infections, rendering prophylaxis and treatment strategies for these patients particularly important. Rapidly evolving clinical research, resulting in the recent advent of various vaccines and therapeutic agents against COVID-19, offers new options to improve care and protection of cancer patients. However, ongoing epidemiological changes and rise of new virus variants require repeated revisions and adaptations of prophylaxis and treatment strategies to meet these new challenges. Therefore, this guideline provides an update on evidence-based recommendations with regard to vaccination, pharmacological prophylaxis and treatment of COVID-19 in cancer patients in light of the currently dominant omicron variants. It was developed by an expert panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) based on a critical review of the most recent available data..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
16 January 2023 2023 |
|---|---|
| Erschienen: |
16 January 2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:181 |
|---|---|
| Enthalten in: |
European journal of cancer - 181(2023), Seite 102-118 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Giesen, Nicola, 1983- [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Online verfügbar 10. Dezember 2022, Artikelversion März 2023 Gesehen am 06.04.2023 |
|---|
| Umfang: |
17 |
|---|
| doi: |
10.1016/j.ejca.2022.11.030 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1841874140 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1841874140 | ||
| 003 | DE-627 | ||
| 005 | 20230927100544.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230406s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2022.11.030 |2 doi | |
| 035 | |a (DE-627)1841874140 | ||
| 035 | |a (DE-599)KXP1841874140 | ||
| 035 | |a (OCoLC)1389530873 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Giesen, Nicola |d 1983- |e verfasserin |0 (DE-588)141844272 |0 (DE-627)631828524 |0 (DE-576)32643657X |4 aut | |
| 245 | 1 | 0 | |a AGIHO guideline on evidence-based management of COVID-19 in cancer patients |b 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants |c Nicola Giesen, Elena Busch, Enrico Schalk, Gernot Beutel, Maria M. Rüthrich, Marcus Hentrich, Bernd Hertenstein, Hans H. Hirsch, Meinolf Karthaus, Yascha Khodamoradi, Philipp Koehler, William Krüger, Michael Koldehoff, Robert Krause, Sibylle C. Mellinghoff, Olaf Penack, Michael Sandherr, Ruth Seggewiss-Bernhardt, Karsten Spiekermann, Rosanne Sprute, Jannik Stemler, Florian Weissinger, Bernhard Wörmann, Hans-Heinrich Wolf, Oliver A. Cornely, Christina T. Rieger, Marie von Lilienfeld-Toal |
| 264 | 1 | |c 16 January 2023 | |
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar 10. Dezember 2022, Artikelversion März 2023 | ||
| 500 | |a Gesehen am 06.04.2023 | ||
| 520 | |a The novel coronavirus SARS-CoV-2 and the associated infectious disease COVID-19 pose a significant challenge to healthcare systems worldwide. Patients with cancer have been identified as a high-risk population for severe infections, rendering prophylaxis and treatment strategies for these patients particularly important. Rapidly evolving clinical research, resulting in the recent advent of various vaccines and therapeutic agents against COVID-19, offers new options to improve care and protection of cancer patients. However, ongoing epidemiological changes and rise of new virus variants require repeated revisions and adaptations of prophylaxis and treatment strategies to meet these new challenges. Therefore, this guideline provides an update on evidence-based recommendations with regard to vaccination, pharmacological prophylaxis and treatment of COVID-19 in cancer patients in light of the currently dominant omicron variants. It was developed by an expert panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) based on a critical review of the most recent available data. | ||
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Guideline | |
| 650 | 4 | |a Haematological malignancy | |
| 650 | 4 | |a Prophylaxis | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Solid tumour | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Vaccination | |
| 700 | 1 | |a Busch, Elena |d 1987- |e verfasserin |0 (DE-588)1073257738 |0 (DE-627)828739145 |0 (DE-576)434772917 |4 aut | |
| 700 | 1 | |a Schalk, Enrico |d 1977- |e verfasserin |0 (DE-588)132983087 |0 (DE-627)529568519 |0 (DE-576)299544303 |4 aut | |
| 700 | 1 | |a Beutel, Gernot |d 1971- |e verfasserin |0 (DE-588)123275881 |0 (DE-627)082455414 |0 (DE-576)293633711 |4 aut | |
| 700 | 1 | |a Rüthrich, Maria Madeleine |d 1990- |e verfasserin |0 (DE-588)1203565593 |0 (DE-627)1688544569 |4 aut | |
| 700 | 1 | |a Hentrich, Marcus |e verfasserin |0 (DE-588)108845075X |0 (DE-627)849565405 |0 (DE-576)45920923X |4 aut | |
| 700 | 1 | |a Hertenstein, Bernd |d 1958- |e verfasserin |0 (DE-588)132885816 |0 (DE-627)527586374 |0 (DE-576)175339902 |4 aut | |
| 700 | 1 | |a Hirsch, Hans H. |e verfasserin |0 (DE-588)1150682086 |0 (DE-627)1010880551 |0 (DE-576)497184923 |4 aut | |
| 700 | 1 | |a Karthaus, Meinolf |e verfasserin |0 (DE-588)110269357 |0 (DE-627)537491910 |0 (DE-576)289668204 |4 aut | |
| 700 | 1 | |a Khodamoradi, Yascha |e verfasserin |4 aut | |
| 700 | 1 | |a Köhler, Philipp |d 1988- |e verfasserin |0 (DE-588)1033465666 |0 (DE-627)741273853 |0 (DE-576)381060624 |4 aut | |
| 700 | 1 | |a Krüger, William H. |e verfasserin |0 (DE-588)1206346620 |0 (DE-627)1692338781 |4 aut | |
| 700 | 1 | |a Koldehoff, Michael |e verfasserin |0 (DE-588)1206348569 |0 (DE-627)169234241X |4 aut | |
| 700 | 1 | |a Krause, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Mellinghoff, Sibylle Christiane |d 1990- |e verfasserin |0 (DE-588)112248822X |0 (DE-627)875699855 |0 (DE-576)481342443 |4 aut | |
| 700 | 1 | |a Penack, Olaf |d 1971- |e verfasserin |0 (DE-588)123860938 |0 (DE-627)706454561 |0 (DE-576)293914265 |4 aut | |
| 700 | 1 | |a Sandherr, Michael |d 1963- |e verfasserin |0 (DE-588)120841843 |0 (DE-627)705030229 |0 (DE-576)292411561 |4 aut | |
| 700 | 1 | |a Seggewiß-Bernhardt, Ruth |d 1972- |e verfasserin |0 (DE-588)123726441 |0 (DE-627)082730881 |0 (DE-576)293847037 |4 aut | |
| 700 | 1 | |a Spiekermann, Karsten |e verfasserin |4 aut | |
| 700 | 1 | |a Sprute, Rosanne |e verfasserin |0 (DE-588)1209782375 |0 (DE-627)169775693X |4 aut | |
| 700 | 1 | |a Stemler, Jannik |e verfasserin |0 (DE-588)119889802X |0 (DE-627)1681072009 |4 aut | |
| 700 | 1 | |a Weißinger, Florian |d 1963- |e verfasserin |0 (DE-588)172446783 |0 (DE-627)697386481 |0 (DE-576)133309029 |4 aut | |
| 700 | 1 | |a Wörmann, Bernhard |e verfasserin |0 (DE-588)111178969X |0 (DE-627)865896577 |0 (DE-576)476257093 |4 aut | |
| 700 | 1 | |a Wolf, Hans-Heinrich |e verfasserin |0 (DE-588)111507790 |0 (DE-627)691118140 |0 (DE-576)30671227X |4 aut | |
| 700 | 1 | |a Cornely, Oliver Andreas |d 1967- |e verfasserin |0 (DE-588)121712915 |0 (DE-627)081485123 |0 (DE-576)292844425 |4 aut | |
| 700 | 1 | |a Rieger, Christina |d 1975- |e verfasserin |0 (DE-588)124900690 |0 (DE-627)367769875 |0 (DE-576)294559108 |4 aut | |
| 700 | 1 | |a Lilienfeld-Toal, Marie von |d 1971- |e verfasserin |0 (DE-588)121251268 |0 (DE-627)081183585 |0 (DE-576)29260937X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1965 |g 181(2023), Seite 102-118 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-2995 |7 nnns |
| 773 | 1 | 8 | |g volume:181 |g year:2023 |g pages:102-118 |g extent:17 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2022.11.030 |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804922017804 |x Verlag |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_178 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 951 | |a AR | ||
| 952 | |d 181 |j 2023 |h 102-118 |g 17 | ||
| 980 | |2 178 |1 01 |x 3178 |b 4379063852 |y x |z 26-09-23 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 4303713090 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 06-04-23 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 4381210336 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 04-10-23 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://doi.org/10.1016/j.ejca.2022.11.030 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://www.sciencedirect.com/science/article/pii/S0959804922017804 | ||
| 982 | |2 178 |1 00 |x 3178 |8 00 |0 (DE-627)504385097 |a Universitätsklinik für Hämatologie und Onkologie <Magdeburg> | ||
| 982 | |2 178 |1 00 |x 3178 |8 01 |a Schalk, Enrico / KHAE | ||
| 982 | |2 178 |1 00 |x 3178 |8 02 |0 (DE-627)719906830 |a begutachteter Zeitschriftenartikel (peer reviewed) | ||
| 982 | |2 178 |1 00 |x 3178 |8 03 |a Open Access | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2023 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_27 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_17 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1516122984 |a Busch, Elena | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)169133667X |a Zentrum für Innere Medizin (Krehl Klinik) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_2 | ||
| 983 | |2 178 |1 00 |x 3178 |8 00 |a Impact factor: 8.4 | ||
| 983 | |2 178 |1 01 |x 3178 |8 99 |a j2023 | ||